Baxter

• A02 - Agentes para el tratamiento de alteraciones causadas por ácidos
• LOSEC gastro-resistant capsule, hard 20 mg
• LOSEC gastro-resistant capsule, hard 40 mg
• B01 - Agentes antitrombóticos
• CEPROTIN powder and solvent for solution for injection 1 000 IU+10 ml
• CEPROTIN powder and solvent for solution for injection 500 IU+5 ml
• J01 - Antibacterianos para uso sistémico
• METRONIDAZOL solution for infusion 1 000 mg/200 ml
• METRONIDAZOL solution for infusion 1 500 mg/300 ml
• METRONIDAZOL solution for infusion 500 mg/100 ml
• J06 - Sueros inmunes e inmunoglobulinas
• KIOVIG solution for infusion 1 g/10 ml
• KIOVIG solution for infusion 10 g/100 ml
• KIOVIG solution for infusion 2.5 g/25 ml
• KIOVIG solution for infusion 20 g/200 ml
• KIOVIG solution for infusion 5 g/50 ml
• J07 - Vacunas
• INFLUJECT suspension for injection
• NEISVAC C suspension for injection
• L01 - Antineoplásicos
• ENDOXAN coated tablet 50 mg
• ENDOXAN powder for solution for injection 1 g
• ENDOXAN powder for solution for injection 100 mg
• ENDOXAN powder for solution for injection 200 mg
• ENDOXAN powder for solution for injection 500 mg
• HOLOXAN powder for solution for injection 1 000 mg
• HOLOXAN powder for solution for injection 2 000 mg
• HOLOXAN powder for solution for injection 200 mg
• HOLOXAN powder for solution for injection 500 mg
• L02 - Terapia endocrina
• FARESTON tablet 60 mg
• HONVAN tablet 120 mg
• N01 - Anestésicos
• AERRANE nebuliser solution
• SUPRANE inhalation vapour, liquid 351.6 g/240 ml
• V03 - Todos los demás preparados terapéuticos
• UROMITEXAN film-coated tablet 400 mg
• UROMITEXAN film-coated tablet 600 mg
• UROMITEXAN solution for infusion 1 g/10 ml
• UROMITEXAN solution for infusion 200 mg/2 ml
• UROMITEXAN solution for infusion 400 mg/4 ml